Life Biosciences Secures $80 Million for Cellular Rejuvenation
Life Biosciences, a biotechnology firm based in Boston, Massachusetts, has announced the successful closing of an $80 million Series D funding round on April 8, 2026. The company focuses on rejuvenating cells to reverse and prevent age-related diseases through partial epigenetic reprogramming.
Company Vision and Leadership
Life Biosciences is led by CEO Jerry McLaughlin, who is at the forefront of their mission to combat aging-related diseases. The company’s approach involves using partial epigenetic reprogramming to rejuvenate cells, thereby reversing and preventing conditions associated with aging.
McLaughlin stated, "We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging."
Funding Utilization
The newly acquired funds are earmarked for several key initiatives. Primarily, they will support the Phase 1 clinical trial of the company's lead program, ER-100, which targets optic neuropathies. Additionally, the funds will aid in the exploration of new candidates from Life Biosciences' Partial Epigenetic Reprogramming platform, which aims to address multiple therapeutic indications.
Future Prospects
With the latest funding, Life Biosciences plans to sustain its operations into the second half of 2027. This financial backing will enable the company to reach significant clinical milestones and continue expanding its pipeline of disease-modifying solutions for patients.
No Lead Investor Named
Interestingly, the Series D round did not specify a lead investor or list any participating investors, indicating a broad base of support without disclosing specific entities.
Conclusion
Life Biosciences' continued focus on cellular rejuvenation and its significant Series D funding highlight the growing interest and potential in biotechnological solutions to age-related diseases. With these resources, the company is poised to advance its innovative therapies and potentially improve outcomes for patients worldwide.